リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Monitoring the COVID-19 immune landscape in Japan」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Monitoring the COVID-19 immune landscape in Japan

Sasanami, Misaki Kayano, Taishi Nishiura, Hiroshi 京都大学 DOI:10.1016/j.ijid.2022.06.005

2022.09

概要

[Objectives] COVID-19 vaccination in Japan started on February 17, 2021. Because the timing of vaccination and the risk of severe COVID-19 greatly varied with age, the present study aimed to monitor the age-specific fractions of the population who were immune to SARS-CoV-2 infection after vaccination. [Methods] Natural infection remained extremely rare, accounting for less than 5% of the population by the end of 2021; thus, we ignored natural infection-induced immunity and focused on vaccine-induced immunity. We estimated the fraction of the population immune to infection by age group using vaccination registry data from February 17, 2021, to October 17, 2021. We accounted for two important sources of delay: (i) reporting delay and (ii) time from vaccination until immune protection develops. [Results] At the end of the observation period, the proportion of individuals still susceptible to SARS-CoV-2 infection substantially varied by age and was estimated to be ≥90% among people aged 0–14 years, in contrast to approximately 20% among the population aged ≥65 years. We also estimated the effective reproduction number over time using a next-generation matrix while accounting for differences in the proportion immune to infection by age. [Conclusion] The COVID-19 immune landscape greatly varied by age, and a substantial proportion of young adults remained susceptible. Vaccination contributed to a marked decrease in the reproduction number.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

Abu Jabal KA, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill 2021;26:1–5.

Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med 2022;386:1532–46.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403–16.

Belay ED, Godfred-Cato S. SARS-CoV-2 spread and hospitalisations in paediatric pa- tients during the omicron surge. Lancet Child Adolesc Health 2022;6:280–1.

Berselli N, Filippini T, Paduano S, Malavolti M, Modenese A, Gobba F, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in the Northern Italy popula- tion before the COVID-19 second wave. Int J Occup Med Environ Health 2022;35:63–74.

Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 vari- ants and severe COVID-19 disease in Qatar. Nat Med 2021;27:1614–21.

Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS– CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: test nega- tive design study. BMJ 2021;374:n1943.

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412–23.

Elbe S, Data Buckland-Merrett G. disease and diplomacy: GISAID’s innovative con- tribution to global health. Glob Chall 2017;1:33–46.

Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance — VISION network, 10 states, August 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022;71:255–63.

GISAID, 2022, https://www.gisaid.org (accessed 15 June 2022)

Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccina- tion campaign in Israel: an observational study using national surveillance data. Lancet 2021;397:1819–29.

Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vac- cine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 2021;397:1725–35.

Houhamdi L, Gautret P, Hoang VT, Fournier PE, Colson P, Raoult D. Characteristics of the first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, Novem- ber–December 2021. J Med Virol 2022;94:2290–5.

Ito K, Piantham C, Nishiura H. Predicted dominance of variant Delta of SARS-CoV-2 before Tokyo Olympic Games, Japan, July 2021. Euro Surveill 2021;26.

Jentsch PC, Anand M, Bauch CT. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study. Lancet Infect Dis 2021;21:1097–106.

Jordan RE, Adab P, Cheng KK. COVID-19: risk factors for severe disease and death. BMJ 2020;368:m1198.

Kayano T, Lee H, Nishiura H. Modelling a supplementary vaccination program of rubella using the 2012–2013 epidemic data in Japan. Int J Environ Res Public Health 2019;16.

Loconsole D, Bisceglia L, Centrone F, Sallustio A, Accogli M, Dalfino L, et al. Au- tochthonous outbreak of SARS-CoV-2 omicron variant in booster-vaccinated (3 doses) healthcare workers in Southern Italy: just the tip of the iceberg? Vac- cines 2022;10:1–9.

Madhi SA, Kwatra G, Myers JE, Jassat W, Dhar N, Mukendi CK, et al. Population immunity and COVID-19 severity with omicron variant in South Africa. N Engl J Med 2022;386:1314–26.

Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav 2021;5:947–53.

Ministry of Health, Labour and Welfare, 2021a. The situation analysis on COVID-19 and response from MHLW, December 31, 2021. https://www.mhlw.go.jp/stf/newpage_23137.html (accessed 15 June 2022)

Ministry of Health, Labour and Welfare, 2021b. Advisory board for COVID- 19 control, 50th. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_ 00294.html (accessed 15 June 2022)

Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008;5:e74.

Munasinghe L, Asai Y, Nishiura H. Quantifying heterogeneous contact patterns in Japan: a social contact survey. Theor Biol Med Model 2019;16:6.

National Institute of Infectious Diseases, 2021. About new concerning variant of SARS- CoV-2 that may have different infectiousness, transmissibility, and antigenicity (9th report), https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/10434-covid19- 43. html. (accessed 15 June 2022)

Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (COVID-19) infections. Int J Infect Dis 2020;93:284–6.

Nopsopon T, Pongpirul K, Chotirosniramit K, Jakaew W, Kaewwijit C, Kanchana S, et al. Seroprevalence of hospital staff in a province with zero COVID-19 cases. PLoS ONE 2021;16.

Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Com- parative analysis of the risks of hospitalisation and death associated with SARS– CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet 2022;399:1303–12.

Okubo R, Yoshioka T, Ohfuji S, Matsuo T, Tabuchi T. COVID-19 vaccine hesitancy and its associated factors in Japan. Vaccines 2021;9:1–10.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603–15.

Prime Minister’s Office of Japan, 2022. About COVID-19 vaccination 2022, https:// www.kantei.go.jp/jp/headline/kansensho/vaccine.html. (accessed 15 June 2022)

Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta KD, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med 2021;27:1370–8.

Ramírez JD, Castañeda S, Ballesteros N, Muñoz M, Hernández M, Banu R, et al. Hotspots for SARS-CoV-2 omicron variant spread: lessons from New York City. J Med Virol 2022;94:2911–14.

Sasanami M, Kayano T, Nishiura H. The number of COVID-19 clusters in healthcare and elderly care facilities averted by vaccination of healthcare workers in Japan, February–June 2021. Math Biosci Eng 2022;19:2762–73.

Sheikh A, McMenamin J, Taylor B, Robertson C. Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hos- pital admission, and vaccine effectiveness. Lancet 2021;397:2461–2.

Slot E, Hogema BM, Reusken CBEM, Reimerink JH, Molier M, Karregat JHM, et al. Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epi- demic in the Netherlands. Nat Commun 2020;11:5744.

Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. In- terim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers — eight U.S loca- tions, December 2020-March 2021. MMWR Morb Mortal Wkly Rep 2021;70: 495–500.

Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med 2022;28:1063–71.

Tsuzuki S, Lee H, Miura F, Chan YH, Jung SM, Akhmetzhanov AR, et al. Dynamics of the pneumonic plague epidemic in Madagascar, August to October 2017. Euro Surveill 2017;22:1–6.

Veneti L, Bøås H, Bråthen Kristoffersen A, Stålcrantz J, Bragstad K, Hungnes O, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Euro Surveill 2022;27.

Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med 2020;26:1193–5.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る